I19 Normalization of phenotype and reduction of gliosis levels via glutaminyl cyclases inhibition in a huntington disease mouse model

Anne-Christine Plank, S. Schilling, T. Hoffmann, I. Lues, S. Hörsten
{"title":"I19 Normalization of phenotype and reduction of gliosis levels via glutaminyl cyclases inhibition in a huntington disease mouse model","authors":"Anne-Christine Plank, S. Schilling, T. Hoffmann, I. Lues, S. Hörsten","doi":"10.1136/jnnp-2018-EHDN.255","DOIUrl":null,"url":null,"abstract":"Background Huntington disease (HD) may be aggravated by enzymatic activity of glutaminyl cyclase (QC/QPCT) and its isoenzyme (isoQC/QPCTL) via the following mechanisms: Neurotoxic pyroglutamated (pGlu) mutant huntingtin (mHTT) fragments may be formed via N-terminal glutamine cyclization of truncated mHTT species by enzymatic activity of QC and/or isoQC. Subclinical neuroinflammation and gliosis in HD may be triggered via isoQC-dependent maturation of pGlu-CCL2. QC-associated interference in heat shock protein and chaperone levels may promote mHTT cellular toxicity. Aims The present study sought to investigate the role of QC/isoQC in HD via genetic and pharmacological proof-of-concept (POC) experiments targeting the (iso)enzyme in the BACHD mouse model of HD. Methods Genetic POC was achieved by crossbreeding of BACHD with QC-KO/isoQC-KO mice, pharmacological POC by early interventional studies in 6-weeks-old BACHD mice for 18 weeks using increasing dosages of the QC/isoQC inhibitor PQ912 (Probiodrug AG). Several behavioral and physiological end-points including cellular and morphological markers were examined. Results PQ912 treatment resulted in lowered mHTT and GFAP levels, associated with normalization of the abnormal body weight gain and energy metabolism of BACHD mice at 24 weeks of age. PQ912 treatment was well tolerated in a wide range of dosages with no obvious adverse effects. Crossbreeding of iso/QC-KO mice ameliorated the body weight increase and certain behavioral abnormalities in BACHD mice. Conclusion Experiments provide evidence for glutaminyl cyclases to represent a druggable target in HD. Early QC/isoQC-inhibitor-based pharmacological intervention in BACHD mice resulted in clear beneficial effects, including but not limited to a lowering of mHTT. Since the QC/isoQC inhibitor PQ912 is in clinical development for the indication AD, further preclinical and translational studies in HD are tempted.","PeriodicalId":16509,"journal":{"name":"Journal of Neurology, Neurosurgery & Psychiatry","volume":"260 1","pages":"A95 - A95"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology, Neurosurgery & Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jnnp-2018-EHDN.255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Huntington disease (HD) may be aggravated by enzymatic activity of glutaminyl cyclase (QC/QPCT) and its isoenzyme (isoQC/QPCTL) via the following mechanisms: Neurotoxic pyroglutamated (pGlu) mutant huntingtin (mHTT) fragments may be formed via N-terminal glutamine cyclization of truncated mHTT species by enzymatic activity of QC and/or isoQC. Subclinical neuroinflammation and gliosis in HD may be triggered via isoQC-dependent maturation of pGlu-CCL2. QC-associated interference in heat shock protein and chaperone levels may promote mHTT cellular toxicity. Aims The present study sought to investigate the role of QC/isoQC in HD via genetic and pharmacological proof-of-concept (POC) experiments targeting the (iso)enzyme in the BACHD mouse model of HD. Methods Genetic POC was achieved by crossbreeding of BACHD with QC-KO/isoQC-KO mice, pharmacological POC by early interventional studies in 6-weeks-old BACHD mice for 18 weeks using increasing dosages of the QC/isoQC inhibitor PQ912 (Probiodrug AG). Several behavioral and physiological end-points including cellular and morphological markers were examined. Results PQ912 treatment resulted in lowered mHTT and GFAP levels, associated with normalization of the abnormal body weight gain and energy metabolism of BACHD mice at 24 weeks of age. PQ912 treatment was well tolerated in a wide range of dosages with no obvious adverse effects. Crossbreeding of iso/QC-KO mice ameliorated the body weight increase and certain behavioral abnormalities in BACHD mice. Conclusion Experiments provide evidence for glutaminyl cyclases to represent a druggable target in HD. Early QC/isoQC-inhibitor-based pharmacological intervention in BACHD mice resulted in clear beneficial effects, including but not limited to a lowering of mHTT. Since the QC/isoQC inhibitor PQ912 is in clinical development for the indication AD, further preclinical and translational studies in HD are tempted.
I19亨廷顿病小鼠模型中通过谷氨酰胺环化酶抑制实现表型正常化和胶质细胞增生水平降低
谷氨酰环化酶(QC/QPCT)及其同工酶(isoQC/QPCTL)的酶活性可能通过以下机制使亨廷顿病(HD)恶化:神经毒性热谷氨酸(pGlu)突变体亨廷顿蛋白(mHTT)片段可能通过QC和/或isoQC的酶活性通过截断mHTT种的n端谷氨酰胺环化而形成。HD患者的亚临床神经炎症和神经胶质瘤可能通过依赖于isoqc的pGlu-CCL2成熟触发。qc相关的热休克蛋白和伴侣蛋白水平的干扰可能促进mHTT细胞毒性。本研究旨在通过针对(iso)酶在HD小鼠BACHD模型中的遗传和药理学概念验证(POC)实验,探讨QC/isoQC在HD中的作用。方法通过与QC- ko /isoQC- ko小鼠杂交获得遗传POC,通过增加QC/isoQC抑制剂PQ912 (Probiodrug AG)剂量对6周龄BACHD小鼠进行18周的早期干预研究获得药理学POC。几个行为和生理终点,包括细胞和形态标记进行了检查。结果PQ912治疗导致mHTT和GFAP水平降低,与24周龄BACHD小鼠异常体重增加和能量代谢正常化有关。PQ912在大剂量范围内耐受性良好,无明显不良反应。iso/QC-KO小鼠杂交可改善BACHD小鼠的体重增加和某些行为异常。结论实验证明谷氨酰胺环化酶是HD的一个可药物靶点。早期以QC/ isoqc抑制剂为基础的药物干预对BACHD小鼠产生了明显的有益效果,包括但不限于mHTT的降低。由于QC/isoQC抑制剂PQ912正处于针对AD的临床开发阶段,因此对HD的进一步临床前和转化研究受到了吸引。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信